Nureca Valuation

Is NURECA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of NURECA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: NURECA (₹274.05) is trading above our estimate of fair value (₹183.61)

Significantly Below Fair Value: NURECA is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for NURECA?

Key metric: As NURECA is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for NURECA. This is calculated by dividing NURECA's market cap by their current revenue.
What is NURECA's PS Ratio?
PS Ratio	3x
Sales	₹908.02m
Market Cap	₹2.78b

NURECA key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	2.8x
Enterprise Value/EBITDA	-17x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does NURECA's PS Ratio compare to its peers?

The above table shows the PS ratio for NURECA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	4.7x
538401 Maestros Electronics & Telecommunications Systems	2.2x	n/a	₹747.7m
527005 Shree Pacetronix	2.2x	n/a	₹436.2m
TAKE TAKE Solutions	3.8x	n/a	₹2.5b
543346 Aashka Hospitals	10.5x	n/a	₹2.6b
NURECA Nureca	3x	n/a	₹2.8b

Price-To-Sales vs Peers: NURECA is good value based on its Price-To-Sales Ratio (3x) compared to the peer average (4.7x).

Price to Sales Ratio vs Industry

How does NURECA's PS Ratio compare vs other companies in the Asian Medical Equipment Industry?

30 Companies	Price / Sales	Estimated Growth	Market Cap

30 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: NURECA is good value based on its Price-To-Sales Ratio (3x) compared to the Asian Medical Equipment industry average (3.3x).

Price to Sales Ratio vs Fair Ratio

What is NURECA's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

NURECA PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	3x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate NURECA's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Medico Intercontinental

₹557.2m

Trades in pharmaceutical products.

539938

₹61.29

33.1%

-27.8%

Dr Lalchandani Labs

₹81.2m

Provides diagnostic and related healthcare tests and services in India.

541299

₹18.73

4.1%

-46.5%

N G Industries

₹566.9m

Provides various healthcare services in India.

530897

₹168.05

0.2%

2.7%